2月25日，海利生物涨0.20%，成交额7957.39万元。两融数据显示，当日海利生物获融资买入额351.46 万元，融资偿还667.39万元，融资净买入-315.93万元。截至2月25日，海利生物融资融券余额合计1.45 亿元。 机构持仓方面，截止2025年9月30日，海利生物十大流通股东中，国泰中证畜牧养殖ETF（159865）位 居第五大流通股东，持股1022.79万股，相比上期增加369.87万股。 责任编辑：小浪快报 资料显示，上海海利生物技术股份有限公司位于上海市黄浦区淮海中路138号805室，成立日期1981年7 月18日，上市日期2015年5月15日，公司主营业务涉及体外诊断试剂（IVD）和口腔组织修复与再生材 料业务。主营业务收入构成为：口腔71.34%，IVD28.61%，其他0.05%。 截至9月30日，海利生物股东户数3.38万，较上期增加7.16%；人均流通股19196股，较上期减少6.68%。 2025年1月-9月，海利生物实现营业收入1.50亿元，同比减少14.15%；归母净利润2032.97万元，同比增 长0.77%。 分红方面，海利生物A股上市后累计派现2.09亿元。近三年， ...

Core Viewpoint - The acquisition of a 41% stake in Shaanxi Ruisheng Biotechnology Co., Ltd. by Shanghai Haili Biotechnology Co., Ltd. is primarily a means to offset a transaction price difference due to declining performance of Ruisheng Biotech, which has been impacted by increased competition and policy changes [2][3][4]. Group 1: Acquisition Details - On November 30, Haili Biotech signed an agreement to acquire a 41% stake in Ruisheng Biotech from Meilun Management Co., Ltd. [2] - The original acquisition of 55% of Ruisheng Biotech was completed in October 2024 for 935 million yuan, with performance guarantees set for the following years [3]. - Due to a decline in Ruisheng's performance starting in Q2 2024, Haili Biotech adjusted the valuation of the acquisition, reducing the price from 935 million yuan to 535.7 million yuan, resulting in a price difference of approximately 399.3 million yuan that Meilun was unable to pay in cash [3][4]. Group 2: Financial Performance - Ruisheng Biotech's revenue for 2024 and the first nine months of 2025 was 265 million yuan and 105 million yuan, respectively, with net profits of 139 million yuan and 43.06 million yuan [5]. - The valuation of Ruisheng Biotech was adjusted to 974 million yuan, reflecting a significant increase from its book value of 301 million yuan, resulting in a valuation increase of 673 million yuan, or 223.21% [6]. - Haili Biotech's revenue for 2024 was 271 million yuan, a 12.59% increase year-on-year, with a net profit of 171 million yuan, representing a 172.28% increase [7]. Group 3: Market Challenges - Haili Biotech's main businesses, including in vitro diagnostic reagents and oral tissue repair materials, are facing pressures due to intensified market competition and declining product prices [8]. - In Q3 2025, Haili Biotech experienced a significant revenue decline of 40.2% year-on-year, with total revenue of 150 million yuan, a 14.15% decrease compared to the previous year [8].

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the status of the funds raised by Seirus Medical Technology Group Co., Ltd. It highlights the termination of certain fundraising projects and the reallocation of remaining funds to enhance liquidity and operational efficiency in response to changing market conditions. Fundraising Overview - In 2018, the company raised approximately RMB 625.96 million through a non-public offering of A-shares, with a net amount of RMB 607.61 million after expenses [1][2] - As of June 30, 2025, the remaining balance of the non-public fundraising was RMB 8.99 million, including interest [2] Fund Usage and Management - By June 30, 2025, the company had utilized RMB 202.78 million of the funds raised from the 2020 convertible bond issuance, leaving a balance of RMB 333.89 million [4] - The company has established dedicated bank accounts for the management of the raised funds, ensuring compliance with regulatory requirements [7][18] Project Termination and Fund Reallocation - The company decided to terminate the "Expansion of Medical Testing Integrated Marketing and Service Business Scale Project" due to significant changes in the market environment and profitability concerns, reallocating the remaining RMB 172.54 million to enhance liquidity [28][29] - The decision was made after thorough evaluations and was approved in board meetings held in June 2025 [28] Financial Management Practices - The company has implemented a structured approach to manage the raised funds, including regular audits and checks by the finance department to ensure proper usage [7][24] - The company has also utilized idle funds temporarily to supplement working capital, with repayments made as scheduled [24][31] Regulatory Compliance - The company has adhered to various regulations regarding fundraising and fund management, including the establishment of tripartite agreements with banks and sponsors to ensure proper oversight [7][18][22]